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Background. We investigated associations between interferon (IFN)–g–inducible protein (IP)–10 and liver
histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV)
genotypes 1–4.
Methods. Plasma IP-10 was monitored before, during, and after treatment with pegylated IFN-a2a and ribavirin
in 265 HCV-infected patients.
Results. In univariate analyses, a low baseline IP-10 level was significantl associated with low baseline viral
load, rapid viral response (RVR), a sustained viral response (SVR), body mass index !25 kg/m2, and less-pronounced
fib osis, inflammation and steatosis (for HCV genotypes other than 3). When the results of the univariate analyses
were included in multivariate analyses, a low plasma IP-10 level, low baseline viral load, and genotype 2 or 3
infection were independent predictors of an RVR and SVR. IP-10 levels decreased 6 weeks into treatment and
remained low in patients with an SVR. By contrast, plasma levels of IP-10 rebounded in patients who had detectable
HCV RNA after the completion of treatment. Using cutoff IP-10 levels of 150 and 600 pg/mL for predicting an
SVR in patients infected with HCV genotype 1 yielded a specificit and sensitivity of 81% and 95%, respectively.
Conclusion. Baseline IP-10 levels are predictive of the response to HCV treatment.
Hepatitis C virus (HCV) is the major cause of paren-
terally transmitted non-A, non-B hepatitis [1, 2] and
is associated with chronic hepatitis, cirrhosis, and he-
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patocellular carcinoma [3, 4]. With currently available
treatment with pegylated (PEG)–interferon (IFN)–a and
ribavirin, a sustained viral response (SVR) is achieved
in 50%–80% of infected individuals after the comple-
tion of treatment [5–7]. Factors independently asso-
ciated with a favorable outcome after therapeutic in-
tervention include infection with an HCV genotype
other than 1, viral loads ! copies/mL, a body62 10
surface area !2 m2, age !40 years, the absence of bridg-
ing fib osis or cirrhosis in pretreatment liver-biopsy
samples, and a rapid viral response (RVR) after the
onset of treatment [5–10].
The 10-kDa IFN-g–inducible protein (IP-10 or
CXCL10) is a chemotactic CXC chemokine of 77 aa in
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Table 1. Baseline characteristics of the patients, grouped by interferon-g–inducible protein
(IP)–10 level before treatment.
Characteristic
IP-10 level
!150 pg/mL 150–600 pg/mL 1600 pg/mL
Age, mean  SD, years 38.9  8.3 42.6  10.7 42.5  10.5
Sex, no. (%)
Male 62 (77) 102 (67) 14 (44)
Female 19 (23) 50 (33) 18 (56)
BMI, mean  SD, kg/m2 24.5  3.6 25.3  3.3 25.8  4.8
HCV genotype, 1/2/3/4/5 47/10/18/5/1 102/13/29/8/0 24/1/6/1/0
HCV-RNA load, mean  SD, log10 IU/mL 6.0  0.7 6.1  0.7 6.4  0.6
Normalized ALT (ALT/ULN), mean  SD 2.1  1.5 2.5  0.2 3.1  1.9
Normalized AST (AST/ULN), mean  SD 1.1  0.6 1.9  1.5 2.4  1.7
Ishak protocol scores
Fibrosis stage, 0/1/2/3/4/5/6 3/34/18/8/5/4/1 8/26/40/16/14/13/9 1/4/9/6/1/3/5
Interface hepatitis grade, 0/1/2/3/4 8/36/23/6/0 7/50/45/24/0 1/7/14/6/0
Focal inflammation grade, 0/1/2/3/4 0/17/44/12/0 2/20/69/35/0 0/5/13/10/0
Portal inflammation grade, 0/1/2/3/4 3/44/28/1/0 4/47/62/13/0 1/7/17/3/0
Steatosis grade, 0/1/2/3 37/23/9/4 56/49/19/2 10/13/3/2
NOTE. Ishak protocols are described in [31]. ALT, alanine aminotransferase; ASP, aspartate aminotransferase;
HCV, hepatitis C virus; ULN, upper limit of normal.
its mature form [11, 12]. Unlike other CXC chemokines, IP-
10 lacks chemotactic activity for neutrophils—rather, it appears
to target T lymphocytes, NK cells, and monocytes [12–14]
through its receptor, CXCR3 [15, 16]. IP-10 can be produced
by a variety of cells, including hepatocytes [17, 18], and it has
been implicated in the pathophysiological progression of mul-
tiple sclerosis [19, 20], diabetes mellitus [21, 22], and HIV [23,
24]. In the setting of HCV infection, IP-10 mRNA expression
in the liver has been reported to be associated with the presence
of lobular necroinflammato y activity in liver-biopsy samples
but not with portal inflammatio or fib osis [18]. Recently,
baseline levels of IP-10 before the initiation of therapeutic in-
tervention for HCV infection were reported to be higher in
patients who did not achieve an SVR after the completion of
treatment [25, 26], especially in the context of HCV genotype
1 infection. The aim of the present study was to investigate
plasma IP-10 levels in patients with chronic HCV infection
before, during, and after combination treatment with PEG–
IFN-a2a and ribavirin and to examine possible associations
with pretreatment liver histological results, initial viral kinetic
reductions during treatment, and fina treatment outcome in
patients infected with HCV genotypes 1, 2, 3, and 4, as well as
to propose possible cutoff values for pretreatment IP-10 levels
for the prognostication of fina treatment outcome.
PATIENTS, MATERIALS, AND METHODS
Patients. Between February 2001 and November 2003, 270
patients (180 men and 90 women) were recruited in a phase
3, open-label, randomized, multicenter trial conducted by the
Dynamically Individualized Treatment of Hepatitis C Infection
and Correlates of Viral/Host Dynamics study group at 9 centers
in France, Germany, Greece, Israel, Italy, The Netherlands,
Spain, Sweden, and Switzerland, as reported elsewhere [27]. All
patients were adults (mean  SD age, years), had41.6 10.2
compensated liver disease, were naive for hepatitis C treatment,
and fulfille the following inclusion criteria: a positive test for
anti-HCV antibodies, a viral load 11000 IU/mL, and 2 serum
alanine aminotransferase values above the upper limit of nor-
mal within 6 months of the initiation of treatment. Baseline
characteristics of the patients are shown in table 1.
Treatment. All patients were initially treated for 6 weeks
with 180 mg of PEG–IFN-a2a subcutaneously once weekly
(Pegasys; Hoffmann–La Roche) and ribavirin orally twice daily
(Copegus; Hoffmann–La Roche) at a total daily dose of 1000
mg for patients weighing !75 kg and 1200 mg daily for those
weighing 75 kg. After 6 weeks of treatment, one-half of the
patients were randomized on the basis of their viral kinetic
classification as outlined below, to receive individualized treat-
ment or to continue receiving standard combination treatment
for a total of 48 weeks.
Viral loads. The plasma viral load was determined by re-
verse-transcription polymerase chain reaction using the Cobas
Amplicor HCV Monitor (version 2.0; Roche Diagnostics) HCV
RNA quantificatio was performed on days 0, 1, 4, 7, 8, 15,
22, and 29; at the end of treatment; and 24 months after the
completion of treatment.
Classificatio of the viral kinetic response. Patients were
classifie as rapid viral responders, slow partial responders, fla
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Figure 1. Kaplan-Meier curve of cumulative hepatitis C virus (HCV) RNA negativity (defined as plasma viral loads 50 IU/mL) during the first 12
weeks of treatment. Patients are grouped as having interferon-g–inducible protein (IP)–10 concentrations  or !150 pg/mL at baseline, before the
onset of combination treatment with pegylated interferon-a2a and ribavirin for HCV genotype 1 (np169) (A), genotype 2 (np24) (B), genotype 3
( ) (C), and genotype 4 ( ) (D) infection. P values were obtained using the log-rank test.np 53 np 14
partial responders, or null responders, according to the indi-
vidual decrease in serum viral loads during the firs 4 weeks
of treatment; they were then randomized within each viral ki-
netic class either to receive an individualized treatment regimen
or to a control group, as reported elsewhere [27]. An RVR was
define as a 2-log reduction in viral load during the firs 4
weeks of treatment and a second-phase decline of 0.09/day.
Investigators and patients were blinded to viral load results until
the randomization after 6 weeks of treatment.
Classificatio of treatment outcome. Patients were classi-
fie as having an SVR if the serum viral load was undetectable
24 weeks after the completion of treatment. Patients were clas-
sifie as having a relapse if the serum viral load was undetectable
at end of treatment but detectable 24 weeks after the completion
of treatment. Patients were classifie as nonresponders if HCV
RNA was detectable in serum at the end of treatment and 24
weeks after the completion of treatment.
Genotyping. Genotyping of HCV was performed using the
INNO-LiPA HCV II device (Innogenetics). In total, 178 patients
were infected with HCV genotype 1, 24 with genotype 2, 53
with genotype 3, 14 with genotype 4, and 1 with genotype 5.
IP-10 quantification Human IP-10 was quantifie using
Quantikine (R&D Systems)—a solid-phase ELISA—on plasma
samples obtained during the week before the start of treatment,
6 weeks after the start of treatment, and 12 weeks after the
completion of treatment. Of the 270 patients included in the
study, plasma samples from 265 were available for analysis at
baseline (i.e., before the onset of combination treatment), 254
were available 6 weeks after the start of treatment, and 80 were
available for analysis 12 weeks after the completion of treat-
ment. All samples were stored at 70C until assay. When IP-
10 levels in serum were analyzed in samples from 24 healthy,
HCV-negative blood donors, a mean  SD level of 87 45
pg/mL (median, 76 pg/mL) was noted.
Liver biopsies. Liver-biopsy samples had been obtained
from all patients within 12 months preceding their inclusion
in the study. Only biopsies with a length 1 cm and that
contained at least 4 portal tracts were evaluated; the majority
of samples had a length 12 cm and contained 16 portal tracts.
In total, liver-biopsy samples from 231 patients were retrieved
and evaluated. For each biopsy, a hematoxylin-eosin stain and
a Sirius Red stain were centrally staged for fib osis and graded
for interface hepatitis, confluen necrosis, focal inflammation
and portal inflammatio by 2 independent observers (J.W. and
M.L., under the supervision of A.P.D.) experienced in the pseu-
donumerical scoring of liver-biopsy samples with a document-
ed acceptable interobserver variability [4, 28–30], in a blinded
fashion, in accordance with the method of Ishak et al. (the
Ishak protocol) [31]. Equivocal issues were debated after the
independent scores were noted, and a consensus score was
obtained. In addition, steatosis was graded as follows: 0, absent;
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Figure 2. Box plot displaying the 10th, 25th, 50th, 75th, and 90th percentiles of interferon-g–inducible protein (IP)–10 levels. Levels were determined
at baseline, before the onset of combination treatment with pegylated interferon-a2a and ribavirin, 6 weeks after starting treatment and 12 weeks
after the completion of treatment, in relation to the final treatment outcome. Patients were grouped by infection hepatitis C virus genotypes 1 and
4 (A) or genotypes 2 and 3 (B).
1, !30% of hepatocytes involved; 2, 30%–70% of hepatocytes
involved; and 3, 170% of hepatocytes involved [30].
Statistical methods. Individual characteristics between
groups were evaluated using the Wilcoxon–Mann-Whitney U
test. Reductions in viral load were displayed in Kaplan-Meier
cumulative survival plots in which survival was define as hav-
ing a serum viral load 150 IU/mL (the limit of detection of
the Cobas Amplicor HCV Monitor version 2.0), with the use
of log-rank tests for comparisons between the Kaplan-Meier
plots. Patients were excluded from this analysis for whom the
time of the firs serum sample with a viral load !50 IU/mL
could not be determined because of missing data ( ). Step-np 5
wise multivariate logistic-regression analyses were performed,
using data from all patients in the study, for which the outcome
variable was dichotomized as either having had an RVR during
the firs 4 weeks of treatment (define as a 2-log reduction
in viral load during the firs 4 weeks of treatment) or not and
achieving an SVR at follow-up week 24 or not. The following
explanatory variables were analyzed in multivariate analyses:
log10 plasma IP-10 level at baseline, log10 viral load at baseline,
genotype, sex, body mass index (BMI), and age. Stepwise mul-
tivariate logistic-regression analysis was performed using the
SAS software package (version 8; SAS Institute). All reported
P values are 2-sided, and was considered to indicateP ! .05
significance
Ethics approval. The treatment study was approved by
ethics committees at each study center and conformed to the
ethical guidelines of the 1975 Declaration of Helsinki. Informed
consent was obtained from each patient included in the study.
RESULTS
A baseline plasma IP-10 level !150 pg/mL (approximately equal
to 2 SDs above mean IP-10 levels in HCV-negative blood do-
nors) was significantl associated with an RVR during the firs
12 weeks of combination treatment in patients infected with
HCV genotypes 1 ( , log-rank test) and 4 ( ,Pp .0003 Pp .01
log-rank test), compared with patients who had baseline plasma
IP-10 levels150 pg/mL. There was also a nonsignifican trend
toward a faster clearance of HCV RNA in serum among the
patients infected with genotypes 2 and 3 and who had lower
baseline plasma IP-10 levels (figu e 1).
Figure 2 shows infected plasma IP-10 levels before, during,
and after treatment in patients grouped as infected with HCV
genotypes 1 and 4 (figu e 2A) or genotypes 2 and 3 (figu e
2B). IP-10 levels at baseline were significantl lower in patients
infected with genotypes 1 and 4 who achieved an SVR than in
those who did not ( ). By contrast, no such differenceP ! .0001
was observed in patients infected with genotypes 2 and 3. After
6 weeks of treatment, IP-10 levels were reduced by 100–200
pg/mL inmost patients, regardless ofHCV genotype, evenamong
nonresponders. Twelve weeks after the completion of treatment,
IP-10 levels remained low in patients who achieved an SVR;
however, among those who relapsed and among nonrespond-
ers, IP-10 levels rebounded to pretreatment levels. The reduc-
tion in IP-10 levels between baseline values and 12 weeks after
the completion of treatment was statistically significan when
patients who achieved an SVR were compared with those who
did not, irrespective of HCV genotype ( ) (figu e 2).Pp .0002
As seen in figu e 3, there was a trend toward lower baseline
IP-10 and HCV Treatment • JID 2006:194 (1 October) • 899
Figure 3. Box plot displaying the 10th, 25th, 50th, 75th, and 90th percentiles of interferon-g–inducible protein (IP)–10 levels. Levels were determined
at baseline, before the onset of combination treatment with pegylated interferon-a2a and ribavirin, in relation to hepatitis C virus (HCV) genotype
(A), baseline viral load (B), and body mass index (BMI) (C).
IP-10 levels in patients infected with HCV genotypes 2 and 3,
compared with patients infected with HCV genotypes 1 and 4,
although this was not statistically significan ( ). A sig-Pp .1
nifican association, however, was noted between the baseline
viral load before the initiation of antiviral treatment and the
baseline IP-10 level. Patients with baseline viral loads 12106
IU/mL thus had significantl higher IP-10 levels than those
with lower viral loads for all genotypes, especially those infected
with genotype 1 (for all genotypes, ; for genotype 1,Pp .05
). Likewise, patients with a BMI 25 kg/m2 (the me-P ! .0001
dian BMI in the study) had significantl higher IP-10 levels at
baseline than those with a BMI !25 kg/m2 ( ). Inter-Pp .009
estingly, neither body weight above or below the median of 75
kg nor height greater than or less than the median of 172 cm
was independently associated with IP-10 levels ( andPp .4
, respectively). Similarly, age above or below 40 yearsPp .1
was not significantl associated with IP-10 levels.
The association between liver histological results and IP-10
levels at baseline is illustrated in figu e 4. There was a trend
toward increasing IP-10 levels with increasing Ishak fib osis
stage; however, a considerable overlap between fib osis stages
was observed. Statistically significantl higher plasma IP-10 lev-
els were seen in patients with bridging fib osis, compared with
those without ( ) and in patients with versus withoutPp .009
cirrhosis ( ). Statistically significan associations betweenPp .03
IP-10 levels and the interface hepatitis score (interface score
2 vs. 3, ), the focal inflammatio score (focal scorePp .0002
2 vs. 3, ), and the portal inflammatio score (portalPp .0015
score 1 vs. 2, ) were observed. As is shown, aPp .0001
significan association between steatosis grade 11 (i.e., involving
130% of hepatocytes) was seen in patients infected with HCV
genotypes other than 3 ( ). In patients infected withPp .01
genotype 3, a nonsignifican trend was observed toward higher
baseline IP-10 levels with increasing steatosis grade ( ).Pp .3
To determine whether IP-10 is an independent predictor of
the initial viral response and the fina treatment outcome, step-
wise multivariate logistic-regression analyses were performed
using plasma IP-10 levels at baseline, viral load at baseline,
genotype, sex, BMI, and patient age as potential explanatory
variables. As seen in table 2, when the outcome variable was
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Figure 4. Box plot displaying the 10th, 25th, 50th, 75th, and 90th percentiles of the interferon-g–inducible protein (IP)–10 levels. Levels were
determined at baseline, before the onset of combination treatment with pegylated (PEG)–interferon-a2a and ribavirin, in relation to Ishak fibrosis stage
[31] (A), the presence or absence of bridging fibrosis (Ishak stage 3) (B), the presence or absence of cirrhosis (Ishak stage 5) (C), Ishak interface
hepatitis grade (D), Ishak focal inflammation grade (E), Ishak portal inflammation grade (F), steatosis grade for hepatitis C virus (HCV) genotypes other
than 3 (G), and steatosis grade for genotype 3 (H).
dichotomized as either having an RVR during the firs 4 weeks
of treatment or not (define as a 2 log reduction in serum
viral load), baseline IP-10 level, baseline viral load, and ge-
notype were independent significan explanatory variables.
When the outcome variable in the stepwise multivariate lo-
gistic-regression analysis was dichotomized as either having an
SVR or not at the end of follow-up, the significan independent
explanatory variables were baseline IP-10 level, baseline viral
load, patient age, and genotype. As was the case with the initial
viral response, genotype was the strongest predictor of fina
treatment outcome, with HCV genotype 3 having the highest
odds ratio (OR). However, baseline IP-10 levels were associated
with a higher OR than baseline viral load and patient age (table
3). IP-10 and genotype remained independent predictors of an
RVR when fib osis stage, interface hepatitis grade, focal inflam
mation grade, portal inflammatio grade, and steatosis grade
were included in the multivariate analysis (data not shown).
Similarly, IP-10 level, baseline viral load, and genotype re-
mained independent predictors of an SVR, whereas age was
replaced by fib osis stage when the liver-biopsy scores were
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Table 2. Multivariate logistic-regression to identify factors predictive of
not achieving a rapid viral response ( ).np 263
Parameter
Regression
coefficient SE
Odds
ratio P
Baseline log10 IP-10 level, pg/mL 2.64 0.52 13.987 !.0001
Baseline log10 viral load, IU/mL 0.53 0.25 1.701 .033
HCV genotype
1 1.28 0.34 0.627 .0002
2 1.10 0.67 0.058 .1006
3 1.93 0.58 0.025 .0008
Constant 10.96 2.02 !.0001
NOTE. IP-10, interferon-g–inducible protein.
Table 3. Multivariate logistic-regression to identify factors predictive
of not achieving a sustained viral response ( ).np 263
Parameter
Regression
coefficient SE
Odds
ratio P
Baseline log10 IP-10 level, pg/mL 1.2 0.43 3.318 .0049
Baseline log10 viral load, IU/mL 0.74 0.28 2.090 .0017
Age, years 0.03 0.01 1.031 .0475
HCV genotype
1 0.76 0.27 0.356 .0059
2 1.26 0.54 0.048 .0192
3 1.29 0.42 0.046 .0020
Constant 9.57 1.83 !.0001
NOTE. HCV, hepatitis C virus; IP-10, interferon-g–inducible protein.
included. However, because not all patients provided liver-bi-
opsy samples, the predictive models generated were not as well
fitte as when liver histological scores were excluded.
When we used cutoff IP-10 levels of 150 and 600 pg/mL for
patients infected with HCV genotype 1, the specificit was 81%
(positive predictive value, 68%) and the sensitivity was 95%
(negative predictive value, 79%). In other words, ∼7 of 10
genotype 1–infected patients who had an IP-10 level 150 pg/
mL before the onset of antiviral treatment achieved an SVR
after the completion of treatment, compared with only 2 of 10
patients who had an IP-10 level 1600 pg/mL. The predictive
value of the IP-10 level was similar, irrespective of whether
patients had received standard or individualized treatment (data
not shown).
DISCUSSION
In the present study, we noted a relatively strong association
between low baseline plasma IP-10 levels and a favorable viral
kinetic response during combination treatment with PEG–IFN-
a2a and ribavirin in patients infected with HCV genotypes 1
and 4. A similar association was observed between low IP-10
levels and SVR. In multivariate analyses, the baseline IP-10 level
was independently predictive of both RVR and the fina treat-
ment outcome. However, in both of these analyses, havingHCV
genotype 2 or 3 infection was associated with higher ORs than
baseline IP-10 levels, which indicates that genotype remains the
strongest predictor of the initial viral response and of the fina
treatment outcome. The OR observed for baseline IP-10 level,
however, was higher than that observed for baseline viral load
with regard to initial viral response and also was higher than
those noted for baseline viral load and patient age with regard
to SVR. Taken together, these data may suggest that IP-10 plays
a role as a readily obtainable baseline variable for the prediction
of an RVR and of the f nal treatment outcome in patients
infected with HCV genotypes 1 and 4.
As seen in figu e 2, there was considerable overlap in baseline
IP-10 levels among the patients infected with HCV genotypes
1 and 4 who achieved an SVR after the completion of treatment,
compared with those who did not. However, when we used
cutoff levels of 150 and 600 pg/mL for patients infected with
HCV genotype 1, the positive predictive value was 68% and
the negative predictive value was 79%. It should, however, be
noted that 59% of the patients infected with HCV genotype 1
in the study had baseline IP-10 levels between 150 and 600 pg/
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mL, which thus limits the predictive value of the baseline IP-
10 level even in patients infected with HCV genotype 1. Sim-
ilarly, almost all patients infected with HCV genotypes 2 and
3 in the study achieved an SVR, which limits the value of the
baseline IP-10 level for predicting outcome in these patients.
A recently completed treatment trial [32] demonstrated that
patients infected with HCV genotypes 2 and 3 who received
16 weeks of treatment had slightly lower rates of SVR than
those who received 24 weeks of treatment. In this setting, it
will be of interest to examine whether IP-10 analysis may be
useful in selecting patients who are suitable for shorter courses
of treatment.
It is noteworthy that several of the factors previously known
to be associated with an increased risk of failure of IFN treat-
ment also were associated with baseline IP-10 levels—that is,
HCV genotype 1 infection with high viral load, high BMI, and
the presence of bridging fib osis or cirrhosis [5–8]. These find
ings may be suggestive that IP-10 plays a role in the antiviral
mechanism of action of IFN-a and ribavirin. However, con-
sidering the observation that IP-10 levels were lower in the
majority of patients 6 weeks after the start of treatment and
rebounded in patients who did not obtain SVR after the com-
pletion of treatment, it appears to be less probable that IP-10
is directly involved in the antiviral effect of combination treat-
ment. More likely, the IP-10 level reflect the degree of local
chemokine signaling in HCV-infected hepatocytes intended to
recruit mononuclear cells to the liver to combat the ongoing
viral infection, as indicated by the association between IP-10
levels and necroinflammato y activity in liver-biopsy samples
(figu e 4). We hypothesize that as intrahepatic viral replication
decreases during treatment, so does chemokine signaling from
infected hepatocytes induced by viral replication. If the virus
is not eradicated after the completion of treatment, intrahepatic
viral replication—and, thus, chemokine signaling—resumes
once antiviral treatment is discontinued. Obviously, we cannot
exclude the possibility that the decrease in IP-10 levels noted
6 weeks after the start of treatment is a direct effect of IFN
and ribavirin and is not only secondary to the decrease in viral
load, especially given that the decrease in IP-10 levels was noted
in all patients, even those without a virological response.
Harvey et al. [18] demonstrated an association between the
expression of IP-10 mRNA in the liver and lobular necroin-
flammato y activity as scored by the Scheuer protocol [33] but
not portal inflammatio or fib osis. By contrast, our results
suggest a statistically significan association between IP-10 levels
as measured in plasma and interface hepatitis, focal inflam
mation, portal inflammation and fib osis stage as scored by
the Ishak protocol [31]. This discrepancy may be due to dif-
ferences in the methods for the quantificatio of IP-10 as well
as in the protocols used for the scoring of liver-biopsy samples.
The correlation between IP-10 levels at baseline and grade 1
steatosis in infection with HCV genotypes other than 3 may
imply that this association might be secondary to an association
between BMI and IP-10 levels. In line with this assumption,
we have previously demonstrated an association between BMI
and steatosis for HCV genotypes other than 3 [30]. The as-
sociation between IP-10 levels and BMI is intriguing, but the
underlying mechanisms remain unclear at present and warrant
further investigation.
The correlation between IP-10 levels and necroinflammato y
activity, fib osis stage, and viral load, as well as the significan
decrease in IP-10 levels after the clearance of the HCV infection
might imply that IP-10 plays a role in the natural pathogenesis
of HCV-induced liver damage, as was suggested by Butera et
al. [25]. Those researchers demonstrated that HCV-infected
hepatocytes produce IP-10. Thus, it is feasible that, after IP-10
production by infected hepatocytes, larger numbers of inflam
matory cells are recruited to the liver, as indicated by the as-
sociation between IP-10 levels and necroinflammato y activity
(figu e 4). If the infection is not overcome during the acute
phase and becomes chronic, the inflammato y response will,
over time, result in increasing fib otic changes. Indeed, it has
previously been shown that long-standing necroinflammato y
activity in the liver, especially in the form of interface hepatitis,
is associated with an accelerated progression of fib osis [4].
In conclusion, we propose that pretreatment plasma IP-10
levels may play a role in predicting the outcome of combination
antiviral treatment in patients infected with HCV genotypes 1
and 4. Thus, low circulating IP-10 levels before the onset of
treatment were associated with a favorable initial reduction in
serum viral loads, as well as with a sustained elimination of
the virus after the completion of treatment. The prognostic
value of IP-10, alone or in conjunction with other prognostic
factors, should be further investigated, and studies should be
performed aiming at definin the putative role of IP-10 in the
resistance to antiviral treatment that is observed in many HCV-
infected patients.
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